Cargando…

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders

AIM: There is discussion whether medicines can be authorized on the market based on evidence from surrogate endpoints. We assessed opinions of different stakeholders on this topic. METHODS: We conducted an online questionnaire that targeted various stakeholder groups (regulatory agencies, pharmaceut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schievink, Bauke, Lambers Heerspink, Hiddo, Leufkens, Hubert, De Zeeuw, Dick, Hoekman, Jarno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182561/ https://www.ncbi.nlm.nih.gov/pubmed/25268242 http://dx.doi.org/10.1371/journal.pone.0108722

Ejemplares similares

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk
por: Idzerda, Nienke M. A., et al.
Publicado: (2018)

Improving clinical trial efficiency by biomarker-guided patient selection
por: Boessen, Ruud, et al.
Publicado: (2014)

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
por: Miao, Y., et al.
Publicado: (2010)

Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
por: Miao, Y., et al.
Publicado: (2011)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
por: ten Ham, Renske M.T., et al.
Publicado: (2018)

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]
por: Roscioni, S. S., et al.
Publicado: (2011)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes
por: Pena, Michelle J., et al.
Publicado: (2015)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjd2ambljhevn3uje9v3qqu8i1